The latest report from data and analytics company, GlobalData, has revealed that the glaucoma market is expected to grow to $3.8 billion in 2026 as a result of the launch of pipeline products. Read more


According to the latest report from GlobalData, pipeline agents in the rheumatoid arthritis space are unlikely to address unmet needs by 2025. Read more


A new pipeline drug, RBP-7000, developed by Indivior for the treatment of schizophrenia, has the potential to improve patient compliance, according to research performed by consulting firm GlobalData. Read more


Mundipharma’s network of independent associated companies has been extended to form a new company called Mundipharma EDO (Early Development in Oncology) with the purpose of building a robust and sustainable pipeline in oncology. Read more